Bringing developers advanced integration, scalability and peripherals all in one chip, Texas Instruments (TI) (NASDAQ: TXN) today announced the Sitara™ AM57x processor family, the highest performance devices in this processor platform. Sitara AM57x processors are designed for a broad range of embedded and industrial applications through their unique heterogeneous architecture including ARM® Cortex®-A15 cores for high-performance processing and running a high-level operating system (HLOS). Additionally, AM57x processors integrate TI’s C66x digital signal processors (DSPs) for analytics and real-time computation, programmable real-time units (PRU) and ARM Cortex-M4 cores for control functions, and video and graphic accelerators for advanced user interfaces and multimedia applications, making the AM57x processors unmatched in their class.
The new Sitara AM57x family of processors was designed from the ground up with high performance and integration in mind. As a result, the processors bring developers unparalleled performance of more than 40 percent greater than quad-core ARM Cortex-A9 processors and 280 percent greater than standard dual-core ARM Cortex-A9 processors found in the broad embedded market.
To view the multimedia release go to:
http://www.multivu.com/players/English/70647530-ti-sitara-am57x-processor/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
This year, parents of nearly 16,000 children in the U.S. will hear the words: “Your child has cancer.” One in five of those children won’t survive. September is Childhood Cancer Awareness Month, and as a leader in the way the world understands, treats and defeats childhood cancer and other life-threatening diseases, St. Jude Children’s Research Hospital® will focus on raising awareness and funds for this very important issue.
Despite significant progress made by St. Jude Children’s Research Hospital, which has helped push the overall childhood cancer survival rates from 20 to more than 80 percent since the hospital opened in 1962, cancer remains the leading cause of death by disease for children over the age of 1. Each year about 175,000 children are diagnosed with cancer worldwide, and 60 percent of these kids don’t have access to modern treatment. For those who win their battles against childhood cancer, victory often comes at a cost as survivors face a much higher risk of experiencing unique long-term health effects later in life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7390851-st-jude-hospital-childhood-cancer-awareness/
